First Patient Treated with the DopaFuse Delivery System

October 27th, 2021

SynAgile is pleased to announce treatment of the first patient with the DopaFuse Delivery System in the SCOL (Study of Continuous Oral Levodopa) clinical trial. The patient was treated at the Luxembourg Institute of Health and the Centre Hospitalier de...

Read More

Advancing the Treatment of Parkinson’s Disease

September 30th, 2021

The Luxembourg Institute of Health (LIH) and the Centre Hospitalier de Luxembourg (CHL) announce the launch of “SCOL” (Study of Continuous Oral Levodopa), a unique international clinical trial aiming to assess the safety, tolerability and...

Read More

SynAgile Takes On Debt to Wrap Up Midphase Trial of Drug Delivery Dental Retainer

September 28th, 2021

The limitations of orally delivered levodopa have inspired a range of novel formulations designed to provide more constant levels of the drug. SynAgile has put its own spin...

Read More

Appointment of Mr. Michael McNamara to Board of Directors and Dr. C. Warren Olanow as Chief Medical Officer

September 22nd, 2021

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its...

Read More

Trial Regulatory Approval in Luxembourg

January 25th, 2021

SynAgile has received approval to begin the SCOL Phase 2 clinical trial in Luxembourg. Professor Rejko Kruger will serve as the Principal Investigator of the study. The study will be conducted at the Luxembourg Institute of Health and the Centre Hospitalier de Luxembourg.

Read More

Trial Regulatory Approval in Italy

January 25th, 2021

SynAgile has received approval to begin the SCOL Phase 2 clinical trial in Italy. Professor Fabrizio Stocchi, MD, PhD will serve as the Principal Investigator of the study. The study will be conducted at three sites: IRCCS San Raffaele Pisana, Policlinico Tor Vergata, and San Raffaele Cassino.

Read More

A Human Factors Study of the DopaFuse Delivery System

September 22nd, 2019

SynAgile presented its findings of a formative Human Factors study at the 2019 International Congress of Parkinson’s Disease and Movement Disorders. View the poster by clicking below.

Read More

Laboratory Performance of the DopaFuse Delivery System

September 22nd, 2019

At the 2019 International Congress of Parkinson’s Disease and Movement Disorders, SynAgile presented its findings of the laboratory performance of the DopaFuse Delivery System. View the poster by clicking below.

Read More

SynAgile Corporation Announces Closing of $10.4M of Financing

August 24th, 2017

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse® technology platform, today announced the closing of a $10.4 million round of equity investment.

Read More

83-year-old invents Parkinson's "Retainer" to deliver Oral Levodopa

March 2nd, 2017

“I would love to see the device widely used by people, while I’m still alive,” says Dr Adam Heller. The 83-year-old research professor at the University of Texas, US, who has more than 260 US patents...

Read More

SynAgile Study Selected for Late Breaking Abstract for MDS 2016

May 27th, 2016

SynAgile's Proof-of-Concept Study was selected as a Late Breaking Abstract for the 2016 Movement Disorders Symposium. View the poster by clicking below.

Read More

SynAgile Corporation Announces Positive Phase 2A Results

October 8th, 2015

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse® intraoral technology platform, today announced positive results from a proof-of-concept...

Read More